A new study has shown a paucity of valuable patient education information regarding surgical or medical treatments for hidradenitis suppurativa (HS) on YouTube.
Psoriasis patients prioritize application feel, non-staining, quick absorption in topical treatment
According to a new study, psoriasis patients reported that application feel, non-staining quality and quick absorption were the most important factors in their preference of topical treatments and in ensuring treatment adherence.
New study shows guselkumab does not increase cancer risk in psoriasis patients
According to a recent study, guselkumab does not increase cancer risk in psoriasis (PsO) patients compared to general and psoriasis populations.
AD linked to higher risk of osteoarthritis
According to a recent study, individuals with atopic dermatitis (AD) and asthma may be more likely to develop osteoarthritis.
Risankizumab shows efficacy in improving plaque psoriasis
According to a recent press release, risankizumab has been shown to be efficacious and safe in patients with plaque psoriasis who have a suboptimal response to IL-17A inhibitors.
Sleep disturbances caused by AD improve over time
According to a new study, sleep disturbances in adults with moderate-to-severe atopic dermatitis (AD) generally improve over time.
Study shows childhood AD increased significantly in Black and multiracial children
New findings show that atopic dermatitis (AD) incidence and prevalence have increased over the last two decades, especially in Black and multiracial children.
Study shows no increased risk for serious infections in pediatric PsO patients on ustekinumab
According to a new study, there is no increased risk of infections in pediatric psoriasis (PsO) patients treated with ustekinumab compared to etanercept or methotrexate.
Psoriasis patients more likely to experience migraines, according to new study
According to a new study, psoriasis patients are significantly more likely to experience migraines than those without psoriasis.
Dupilumab effective in treating severity, decreasing serum biomarkers in pediatric AD patients
Dupilumab was effective in improving disease severity and decreasing severity-associated serum biomarkers in pediatric atopic dermatitis (AD) patients after 28 weeks of treatment, according to real-world evidence from clinical practice.
HealthMinute.TV 